✦ LIBER ✦

P-612 Gefitinib (Iressa, ZD1839) is active as first-line, compassionate use therapy in patients with advanced non-small cell lung cancer (NSCLC)

✍ Scribed by Argiris, Athanassios; Mittal, Namrata; Masters, Gregory

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Gefitinib as first-line, compassionate u

✍ Argiris, Athanassios; Mittal, Namrata 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 90 KB

P-617 Gefitinib (ZD 1839, Iressa) as a l

✍ Haringhuizen, Annebeth; Vaessen, Heleen F.R.; Baas, Paul; van Zandwijk, Nico 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 189 KB

O-243 Clinical benefits in patients with

✍ Janne, Pasi A.; Gurubhagavatula, Sarada; Lucca, Joan; Ostler, Patricia; Skarin, 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 193 KB

Activity of ZD1839 (Gefitinib, Iressa™)

✍ Angelia D. Gibson; Mark Socinski; Chandra P. Belani; Vinay K. Jain 📂 Article 📅 2002 🏛 CIG Media Group, LP. 🌐 English ⚖ 79 KB

P-599 Gefitinib(Iressa) as first-line th

✍ Zimmermann, M.; Luthi, E.; Zouhair, A.; Bauer, J.; Leyvraz, S.; Stupp, R. 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 146 KB

P-587 Experience from a large multi-cent

✍ van Puijenbroek, R.; Bosquée, L.; Tits, G.; Germonpre, P.; Strobbe, E.; Vansteen 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 294 KB